Paul Jackson, Ph.D., is part of the pharmaceutical research team for Janssen Pharmaceuticals — the research and
development sector of Johnson & Johnson.
He has held numerous positions within the company and is currently the Head of Chemistry for Emerging
Sciences. He has designed and established a group focusing on applying medicinal chemistry to non-traditional
areas including nanotechnology, bioconjugation, and chemically modified antibodies, formed a cross-company group to focus on the use of nanotechnology at Johnson & Johnson, led a group of chemists developing surface-modified nanoparticles, and initiated incubators within nanotechnology groups leading to a potential new
therapeutic strategy in oncology.
Prior to his current position, he was U.S. Head for Molecular Sciences for Janssen, and was responsible for the
chemistry, molecular informatics, and structural biology in the U.S. region as part of the global function.
Jackson was previously a group leader for Guilford Pharmaceuticals. He led three New Chemical Entity
programs, one of which advanced into Phase II of trials, and designed and developed the first PMSA ligands that enabled the oncology field to move into clinical trials. He also directed the medicinal chemistry efforts in the cocaine intervention program and served as liaison to the Office of National Drug Control Policy.
Prior to his work at Guilford Pharmaceuticals, Jackson was a chemist for Zeneca Pharmaceuticals where he
developed antagonists at the strychnine-insensitive glycine site of the NMDA receptor for potential therapeutic
intervention in cerebral ischemia and Parkinson’s disease.
He received his bachelor’s degree in biochemistry from Virginia Tech, and both his master’s degree and Ph.D. in organic chemistry from the University of Rochester. Jackson completed his postdoctoral fellowship at the
Massachusetts Institute of Technology.